Kezar Life Sciences Inc (NASDAQ:KZR) — Market Cap & Net Worth
Market Cap & Net Worth: Kezar Life Sciences Inc (KZR)
Kezar Life Sciences Inc (NASDAQ:KZR) has a market capitalization of $923.46K ($923.46K) as of August 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30618 globally and #6131 in its home market, demonstrating a -7.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kezar Life Sciences Inc's stock price $0.13 by its total outstanding shares 7387701 (7.39 Million). Review Kezar Life Sciences Inc (KZR) total liabilities to assess the company's total debt and financial obligations.
Kezar Life Sciences Inc Market Cap History: 2018 to 2026
Kezar Life Sciences Inc's market capitalization history from 2018 to 2026. Data shows change from $1.74 Billion to $923.46K (-59.12% CAGR).
Index Memberships
Kezar Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #902 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2866 of 3165 |
Weight: Kezar Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kezar Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kezar Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.00x
Kezar Life Sciences Inc's market cap is 10.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $69.99 Million | $7.00 Million | -$101.87 Million | 10.00x | N/A |
Competitor Companies of KZR by Market Capitalization
Companies near Kezar Life Sciences Inc in the global market cap rankings as of August 4, 2026.
Key companies related to Kezar Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Kezar Life Sciences Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Kezar Life Sciences Inc's market cap moved from $1.74 Billion to $ 923.46K, with a yearly change of -59.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $923.46K | -98.01% |
| 2025 | $46.47 Million | -6.40% |
| 2024 | $49.65 Million | -29.07% |
| 2023 | $69.99 Million | -86.54% |
| 2022 | $520.09 Million | -57.89% |
| 2021 | $1.24 Billion | +220.31% |
| 2020 | $385.64 Million | +30.17% |
| 2019 | $296.25 Million | -83.01% |
| 2018 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Kezar Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $923.46K USD |
| MoneyControl | $923.46K USD |
| MarketWatch | $923.46K USD |
| marketcap.company | $923.46K USD |
| Reuters | $923.46K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more